Drug Profile

DPM 1003

Alternative Names: DPM-1003

Latest Information Update: 25 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DepYmed
Class Small molecules
Mechanism of Action Protein tyrosine phosphatase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Rett syndrome
New Molecular Entity Yes

Highest Development Phases

Preclinical Rett syndrome

Most Recent Events

19 Mar 2024 US FDA approves IND application for DPM-1003 in Rett syndrome
19 Mar 2024 DepYmed plans a phase I trial for Rett syndrome in 2024
15 Jun 2023 DepYmed intends to files an IND application with the US FDA for Rett syndrome in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com